메뉴 건너뛰기




Volumn 41, Issue 5, 2014, Pages 589-612

GD2-targeted immunotherapy and radioimmunotherapy

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIIDIOTYPIC ANTIBODY; ANTIIDIOTYPIC ANTIBODY 1A7; ANTIIDIOTYPIC ANTIBODY A1G4; ASPARTATE AMINOTRANSFERASE; BETA GLUCAN; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; CYTOKINE; DINUTUXIMAB; DNA VACCINE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; GANGLIOSIDE GD2 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; INTERLEUKIN 2; ISOTRETINOIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 14G2A; MONOCLONAL ANTIBODY 3F8; MONOCLONAL ANTIBODY HU14.18; MONOCLONAL ANTIBODY ME36.1; RADIOISOTOPE; RITUXIMAB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; GANGLIOSIDE; GANGLIOSIDE, GD2;

EID: 84909630359     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.07.003     Document Type: Article
Times cited : (74)

References (135)
  • 1
    • 79958114113 scopus 로고    scopus 로고
    • Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells
    • Yanagisawa M, Yoshimura S, Yu RK. Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells. ASN Neuro. 2011;3.
    • (2011) ASN Neuro , pp. 3
    • Yanagisawa, M.1    Yoshimura, S.2    Yu, R.K.3
  • 2
    • 34248374867 scopus 로고    scopus 로고
    • Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: A novel surface marker for the identification of MSCs
    • Martinez C, Hofmann TJ, Marino R, et al. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood. 2007;109:4245-8.
    • (2007) Blood , vol.109 , pp. 4245-4248
    • Martinez, C.1    Hofmann, T.J.2    Marino, R.3
  • 3
    • 84861801520 scopus 로고    scopus 로고
    • Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis
    • Battula VL, Shi Y, Evans KW, et al. Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest. 2012;122:2066-78.
    • (2012) J Clin Invest , vol.122 , pp. 2066-2078
    • Battula, V.L.1    Shi, Y.2    Evans, K.W.3
  • 4
    • 84875530777 scopus 로고    scopus 로고
    • Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells
    • Liang YJ, Ding Y, Levery SB, et al. Differential expression profiles of glycosphingolipids in human breast cancer stem cells vs. cancer non-stem cells. Proc Natl Acad Sci U S A. 2013;110:4968-73.
    • (2013) Proc Natl Acad Sci U S A , vol.110 , pp. 4968-4973
    • Liang, Y.J.1    Ding, Y.2    Levery, S.B.3
  • 5
    • 0027503907 scopus 로고
    • Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas - An immunohistochemical study
    • Lammie G, Cheung N, Gerald W, et al. Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas - an immunohistochemical study. Int J Oncol. 1993;3:909-15.
    • (1993) Int J Oncol , vol.3 , pp. 909-915
    • Lammie, G.1    Cheung, N.2    Gerald, W.3
  • 6
    • 0022458959 scopus 로고
    • Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins
    • Cheresh DA, Pierschbacher MD, Herzig MA, et al. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins. J Cell Biol. 1986;102:688-96.
    • (1986) J Cell Biol , vol.102 , pp. 688-696
    • Cheresh, D.A.1    Pierschbacher, M.D.2    Herzig, M.A.3
  • 7
    • 0017642531 scopus 로고
    • VCN-releasable sialic acid and gangliosides in human neuroblastomas
    • Shochat SJ, Abt AB, Schengrund CL. VCN-releasable sialic acid and gangliosides in human neuroblastomas. J Pediatr Surg. 1977;12:413-8.
    • (1977) J Pediatr Surg , vol.12 , pp. 413-418
    • Shochat, S.J.1    Abt, A.B.2    Schengrund, C.L.3
  • 8
    • 84877805975 scopus 로고    scopus 로고
    • In silico driven redesign of a clinically relevant antibody for the treatment of gd2 positive tumors
    • Ahmed M, Goldgur Y, Hu J, et al. In silico driven redesign of a clinically relevant antibody for the treatment of gd2 positive tumors. PLoS One. 2013;8:e63359.
    • (2013) PLoS One , vol.8 , pp. e63359
    • Ahmed, M.1    Goldgur, Y.2    Hu, J.3
  • 9
    • 69049089548 scopus 로고    scopus 로고
    • The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research
    • Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323-37.
    • (2009) Clin Cancer Res , vol.15 , pp. 5323-5337
    • Cheever, M.A.1    Allison, J.P.2    Ferris, A.S.3
  • 10
    • 0027447521 scopus 로고
    • Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography
    • Hamilton WB, Helling F, Lloyd KO, et al. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer. 1993;53:566-73.
    • (1993) Int J Cancer , vol.53 , pp. 566-573
    • Hamilton, W.B.1    Helling, F.2    Lloyd, K.O.3
  • 11
    • 0026690779 scopus 로고
    • Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas
    • Chang HR, Cordon-Cardo C, Houghton AN, et al. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer. 1992;70:633-8.
    • (1992) Cancer , vol.70 , pp. 633-638
    • Chang, H.R.1    Cordon-Cardo, C.2    Houghton, A.N.3
  • 12
    • 0023525967 scopus 로고
    • Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma
    • Heiner JP, Miraldi F, Kallick S, et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 1987;47:5377-81.
    • (1987) Cancer Res , vol.47 , pp. 5377-5381
    • Heiner, J.P.1    Miraldi, F.2    Kallick, S.3
  • 13
    • 0036882276 scopus 로고    scopus 로고
    • Disialoganglioside GD2 and a novel tumor antigen: Potential targets for immunotherapy of desmoplastic small round cell tumor
    • Modak S, Gerald W, Cheung NK. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor. Med Pediatr Oncol. 2002;39:547-51.
    • (2002) Med Pediatr Oncol , vol.39 , pp. 547-551
    • Modak, S.1    Gerald, W.2    Cheung, N.K.3
  • 14
    • 0030040191 scopus 로고    scopus 로고
    • Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trial
    • Grant SC, Kostakoglu L, Kris MG, et al. Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur J Nucl Med. 1996;23:145-9.
    • (1996) Eur J Nucl Med , vol.23 , pp. 145-149
    • Grant, S.C.1    Kostakoglu, L.2    Kris, M.G.3
  • 16
    • 0021849979 scopus 로고
    • Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells
    • Cheung NK, Saarinen UM, Neely JE, et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985;45:2642-9.
    • (1985) Cancer Res , vol.45 , pp. 2642-2649
    • Cheung, N.K.1    Saarinen, U.M.2    Neely, J.E.3
  • 17
    • 0023165018 scopus 로고
    • Disialoganglioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth
    • Mujoo K, Cheresh DA, Yang HM, et al. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987;47:1098-104.
    • (1987) Cancer Res , vol.47 , pp. 1098-1104
    • Mujoo, K.1    Cheresh, D.A.2    Yang, H.M.3
  • 18
    • 77957341503 scopus 로고    scopus 로고
    • Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
    • Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324-34.
    • (2010) N Engl J Med , vol.363 , pp. 1324-1334
    • Yu, A.L.1    Gilman, A.L.2    Ozkaynak, M.F.3
  • 19
    • 84877799310 scopus 로고    scopus 로고
    • Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
    • Cheung NK, Guo H, Hu J, et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012;1:477-86.
    • (2012) Oncoimmunology , vol.1 , pp. 477-486
    • Cheung, N.K.1    Guo, H.2    Hu, J.3
  • 20
    • 84909637651 scopus 로고    scopus 로고
    • Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) in patients with relapsed or refractory neuroblastoma (NB) or other GD2-positive solid tumors
    • Basu EM, Kushner B, Modak S, et al. Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) in patients with relapsed or refractory neuroblastoma (NB) or other GD2-positive solid tumors. Advances in Neuroblastoma Research 2014. Cologne. 2014;POC034.
    • (2014) Advances in Neuroblastoma Research 2014. Cologne , pp. POC034
    • Basu, E.M.1    Kushner, B.2    Modak, S.3
  • 21
    • 85059207646 scopus 로고    scopus 로고
    • Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed high-risk neuroblastoma (HR-NB)
    • Kushner B, Cheung IY, Basu EM, et al. Phase I study of anti-GD2 humanized 3F8 (hu3F8) monoclonal antibody (MAb) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with relapsed high-risk neuroblastoma (HR-NB). Advances in Neuroblastoma Research 2014. Cologne. 2014;POC032.
    • (2014) Advances in Neuroblastoma Research 2014. Cologne , pp. POC032
    • Kushner, B.1    Cheung, I.Y.2    Basu, E.M.3
  • 22
    • 84856694163 scopus 로고    scopus 로고
    • Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor
    • Cheung IY, Hsu K, Cheung NK. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2012;30:426-32.
    • (2012) J Clin Oncol , vol.30 , pp. 426-432
    • Cheung, I.Y.1    Hsu, K.2    Cheung, N.K.3
  • 23
    • 84865960648 scopus 로고    scopus 로고
    • Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
    • Tarek N, Le Luduec JB, Gallagher MM, et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest. 2012;122:3260-70.
    • (2012) J Clin Invest , vol.122 , pp. 3260-3270
    • Tarek, N.1    Le Luduec, J.B.2    Gallagher, M.M.3
  • 24
    • 0023525839 scopus 로고
    • Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma
    • Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5:1430-40.
    • (1987) J Clin Oncol , vol.5 , pp. 1430-1440
    • Cheung, N.K.1    Lazarus, H.2    Miraldi, F.D.3
  • 25
    • 0024247485 scopus 로고
    • International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma
    • Brodeur G, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6:1874-81.
    • (1988) J Clin Oncol , vol.6 , pp. 1874-1881
    • Brodeur, G.1    Seeger, R.C.2    Barrett, A.3
  • 26
    • 0026547712 scopus 로고
    • Reassessment of patient response to monoclonal antibody 3F8
    • Cheung NV, Lazarus H, Miraldi FD, et al. Reassessment of patient response to monoclonal antibody 3F8. J Clin Oncol. 1992;10:671-2.
    • (1992) J Clin Oncol , vol.10 , pp. 671-672
    • Cheung, N.V.1    Lazarus, H.2    Miraldi, F.D.3
  • 27
    • 79952762286 scopus 로고    scopus 로고
    • Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: A phase I study
    • Kushner BH, Kramer K, Modak S, et al. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol. 2011;29:1168-74.
    • (2011) J Clin Oncol , vol.29 , pp. 1168-1174
    • Kushner, B.H.1    Kramer, K.2    Modak, S.3
  • 28
    • 0031686971 scopus 로고    scopus 로고
    • Anti-G (D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
    • Cheung NK, Kushner BH, Cheung IY, et al. Anti-G (D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998;16:3053-60.
    • (1998) J Clin Oncol , vol.16 , pp. 3053-3060
    • Cheung, N.K.1    Kushner, B.H.2    Cheung, I.Y.3
  • 29
    • 0024358410 scopus 로고
    • GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma
    • Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood. 1989;73:1936-41.
    • (1989) Blood , vol.73 , pp. 1936-1941
    • Kushner, B.H.1    Cheung, N.K.2
  • 30
    • 0035890643 scopus 로고    scopus 로고
    • Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma
    • Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19:4189-94.
    • (2001) J Clin Oncol , vol.19 , pp. 4189-4194
    • Kushner, B.H.1    Kramer, K.2    Cheung, N.K.3
  • 31
    • 23944499069 scopus 로고    scopus 로고
    • Detecting minimal residual disease in neuroblastoma patients - The present state of the art
    • Beiske K, Ambros PF, Burchill SA, et al. Detecting minimal residual disease in neuroblastoma patients-the present state of the art. Cancer Lett. 2005;228:229-40.
    • (2005) Cancer Lett , vol.228 , pp. 229-240
    • Beiske, K.1    Ambros, P.F.2    Burchill, S.A.3
  • 32
    • 33745528911 scopus 로고    scopus 로고
    • FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor
    • Cheung NK, Sowers R, Vickers AJ, et al. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2006;24:2885-90.
    • (2006) J Clin Oncol , vol.24 , pp. 2885-2890
    • Cheung, N.K.1    Sowers, R.2    Vickers, A.J.3
  • 33
    • 84906234428 scopus 로고    scopus 로고
    • Key role for myeloid cells: Phase II results of anti-G antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma
    • PMID:24644014
    • Cheung NK, Cheung IY, Kramer K, et al. Key role for myeloid cells: phase II results of anti-G antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer. 2014 PMID:24644014.
    • (2014) Int J Cancer
    • Cheung, N.K.1    Cheung, I.Y.2    Kramer, K.3
  • 34
    • 84866623753 scopus 로고    scopus 로고
    • Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission
    • Cheung NK, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol. 2012;30:3264-70.
    • (2012) J Clin Oncol , vol.30 , pp. 3264-3270
    • Cheung, N.K.1    Cheung, I.Y.2    Kushner, B.H.3
  • 36
    • 0036035607 scopus 로고    scopus 로고
    • Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies
    • Cheung NK, Modak S, Vickers A, et al. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. 2002;51:557-64.
    • (2002) Cancer Immunol Immunother , vol.51 , pp. 557-564
    • Cheung, N.K.1    Modak, S.2    Vickers, A.3
  • 37
    • 84886945545 scopus 로고    scopus 로고
    • Anti-GD2 antibody 3F8 and barley-derived (1 - > 3),(1 - > 4)-beta-glucan: A phase I study in patients with chemoresistant neuroblastoma
    • Modak S, Kushner BH, Kramer K, et al. Anti-GD2 antibody 3F8 and barley-derived (1 - > 3),(1 - > 4)-beta-glucan: a phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology. 2013;2:e23402.
    • (2013) Oncoimmunology , vol.2 , pp. e23402
    • Modak, S.1    Kushner, B.H.2    Kramer, K.3
  • 39
    • 85059207549 scopus 로고    scopus 로고
    • Phase I study of haploidentical natural killer (NK) cells plus monoclonal antibody 3F8 for resistant high-risk neuroblastom (HR-NB)
    • Modak M, Cheung NK, Kushner B, et al. Phase I study of haploidentical natural killer (NK) cells plus monoclonal antibody 3F8 for resistant high-risk neuroblastom (HR-NB). Advances in Neuroblastoma Research 2014. Cologne. 2014;OR075.
    • (2014) Advances in Neuroblastoma Research 2014. Cologne , pp. OR075
    • Modak, M.1    Cheung, N.K.2    Kushner, B.3
  • 40
    • 0027145882 scopus 로고
    • Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors
    • Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol. 1994;12:184-93.
    • (1994) J Clin Oncol , vol.12 , pp. 184-193
    • Murray, J.L.1    Cunningham, J.E.2    Brewer, H.3
  • 41
    • 0030929898 scopus 로고    scopus 로고
    • A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: A report of the Children's Cancer Group
    • Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer. 1997;80:317-33.
    • (1997) Cancer , vol.80 , pp. 317-333
    • Frost, J.D.1    Hank, J.A.2    Reaman, G.H.3
  • 42
    • 0023147836 scopus 로고
    • Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity
    • Thurin J, Thurin M, Kimoto Y, et al. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res. 1987;47:1229-33.
    • (1987) Cancer Res , vol.47 , pp. 1229-1233
    • Thurin, J.1    Thurin, M.2    Kimoto, Y.3
  • 43
    • 0024586486 scopus 로고
    • Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides
    • Iliopoulos D, Ernst C, Steplewski Z, et al. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst. 1989;81:440-4.
    • (1989) J Natl Cancer Inst , vol.81 , pp. 440-444
    • Iliopoulos, D.1    Ernst, C.2    Steplewski, Z.3
  • 44
    • 0025021639 scopus 로고
    • Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody
    • Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol. 1990;144:1382-6.
    • (1990) J Immunol , vol.144 , pp. 1382-1386
    • Mueller, B.M.1    Romerdahl, C.A.2    Gillies, S.D.3
  • 45
    • 0026549233 scopus 로고
    • Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma
    • Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas. 1992;3:19-24.
    • (1992) Hum Antibodies Hybridomas , vol.3 , pp. 19-24
    • Saleh, M.N.1    Khazaeli, M.B.2    Wheeler, R.H.3
  • 46
    • 0028946423 scopus 로고
    • A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma
    • Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer. 1995;31A:261-7.
    • (1995) Eur J Cancer , vol.31 A , pp. 261-267
    • Handgretinger, R.1    Anderson, K.2    Lang, P.3
  • 47
    • 0031750167 scopus 로고    scopus 로고
    • Phase I trial of a human-mouse chimeric antidisialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma
    • Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric antidisialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169-80.
    • (1998) J Clin Oncol , vol.16 , pp. 2169-2180
    • Yu, A.L.1    Uttenreuther-Fischer, M.M.2    Huang, C.S.3
  • 48
    • 4444371613 scopus 로고    scopus 로고
    • Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma
    • Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol. 2004;22:3549-57.
    • (2004) J Clin Oncol , vol.22 , pp. 3549-3557
    • Simon, T.1    Hero, B.2    Faldum, A.3
  • 49
    • 78651428141 scopus 로고    scopus 로고
    • Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
    • Simon T, Hero B, Faldum A, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011;11:21.
    • (2011) BMC Cancer , vol.11 , pp. 21
    • Simon, T.1    Hero, B.2    Faldum, A.3
  • 50
    • 0034671441 scopus 로고    scopus 로고
    • Phase I study of chimeric human/murine anti-ganglioside G (D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study
    • Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G (D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol. 2000;18:4077-85.
    • (2000) J Clin Oncol , vol.18 , pp. 4077-4085
    • Ozkaynak, M.F.1    Sondel, P.M.2    Krailo, M.D.3
  • 51
    • 0000230036 scopus 로고    scopus 로고
    • Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: A POG phase II study
    • Yu AL BA, Alvarado C, Rao VJ, Castleberry RP. Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: a POG phase II study. Proc Am Soc Clin Oncol. 1997;16.
    • (1997) Proc Am Soc Clin Oncol , pp. 16
    • Yu, A.L.1    B, A.2    Alvarado, C.3    Rao, V.J.4    Castleberry, R.P.5
  • 52
    • 8944242603 scopus 로고    scopus 로고
    • Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma
    • Murray JL, Kleinerman ES, Jia SF, et al. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996;19:206-17.
    • (1996) J Immunother Emphasis Tumor Immunol , vol.19 , pp. 206-217
    • Murray, J.L.1    Kleinerman, E.S.2    Jia, S.F.3
  • 53
    • 0030756133 scopus 로고    scopus 로고
    • Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients
    • Albertini MR, Hank JA, Schiller JH, et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res. 1997;3:1277-88.
    • (1997) Clin Cancer Res , vol.3 , pp. 1277-1288
    • Albertini, M.R.1    Hank, J.A.2    Schiller, J.H.3
  • 54
    • 84883875530 scopus 로고    scopus 로고
    • Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patients: A SIOPEN phase 1 study
    • Ladenstein R, Weixler S, Baykan B, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patients: a SIOPEN phase 1 study. MAbs. 2013;5:801-9.
    • (2013) MAbs , vol.5 , pp. 801-809
    • Ladenstein, R.1    Weixler, S.2    Baykan, B.3
  • 55
    • 85059207042 scopus 로고    scopus 로고
    • Evaluation of clinical response and survival following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with subcutaneous interleukin-2 in a single center treatment program in high-risk neuroblastoma
    • Lode H, Muller I. Evaluation of clinical response and survival following long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with subcutaneous interleukin-2 in a single center treatment program in high-risk neuroblastoma. Advances in Neuroblastoma Research 2014. Cologne. 2014;PL010.
    • (2014) Advances in Neuroblastoma Research 2014. Cologne , pp. PL010
    • Lode, H.1    Muller, I.2
  • 56
    • 33645280860 scopus 로고    scopus 로고
    • Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma
    • Choi BS, Sondel PM, Hank JA, et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006;55:761-74.
    • (2006) Cancer Immunol Immunother , vol.55 , pp. 761-774
    • Choi, B.S.1    Sondel, P.M.2    Hank, J.A.3
  • 57
    • 84902962349 scopus 로고    scopus 로고
    • Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma
    • 2014
    • Navid F, Sondel PM, Barfield R, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol. 2014;32:1445-52, 2014.
    • (2014) J Clin Oncol , vol.32 , pp. 1445-1452
    • Navid, F.1    Sondel, P.M.2    Barfield, R.3
  • 58
    • 85059207089 scopus 로고    scopus 로고
    • Phase I trial of anti-GD2 humanized 3F8 monoclonal antibody (MAb) combined with subcutaneous interleukin-2 (scIL2) in patients with relapsed neuroblastoma or other GD2-positive solid tumors
    • Roberts SS, Chou AJ, Basu EM, et al. Phase I trial of anti-GD2 humanized 3F8 monoclonal antibody (MAb) combined with subcutaneous interleukin-2 (scIL2) in patients with relapsed neuroblastoma or other GD2-positive solid tumors. Advances in Neuroblastoma Research 2014. Cologne. 2014;POC027.
    • (2014) Advances in Neuroblastoma Research 2014. Cologne , pp. POC027
    • Roberts, S.S.1    Chou, A.J.2    Basu, E.M.3
  • 59
    • 85059207554 scopus 로고    scopus 로고
    • Pharmacokinetics of humanized anti-GD2 monoclonal antibody Hu3F8 in patients with metastatic GD2-positive tumors
    • Cheung IY, Basu EM, Modak M, et al. Pharmacokinetics of humanized anti-GD2 monoclonal antibody Hu3F8 in patients with metastatic GD2-positive tumors. Advances in Neuroblastoma Research 2014. Cologne. 2014;POC037.
    • (2014) Advances in Neuroblastoma Research 2014. Cologne , pp. POC037
    • Cheung, I.Y.1    Basu, E.M.2    Modak, M.3
  • 60
    • 0033928328 scopus 로고    scopus 로고
    • Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma
    • Cheung NK, Guo HF, Heller G, et al. Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res. 2000;6:2653-60.
    • (2000) Clin Cancer Res , vol.6 , pp. 2653-2660
    • Cheung, N.K.1    Guo, H.F.2    Heller, G.3
  • 61
    • 0033958915 scopus 로고    scopus 로고
    • Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2
    • Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol. 2000;18:376-84.
    • (2000) J Clin Oncol , vol.18 , pp. 376-384
    • Foon, K.A.1    Lutzky, J.2    Baral, R.N.3
  • 62
    • 0027336381 scopus 로고
    • Disialoganglioside GD2 anti-idiotypic monoclonal antibodies
    • Cheung NK, Canete A, Cheung IY, et al. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer. 1993;54:499-505.
    • (1993) Int J Cancer , vol.54 , pp. 499-505
    • Cheung, N.K.1    Canete, A.2    Cheung, I.Y.3
  • 63
    • 70350026879 scopus 로고    scopus 로고
    • Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma
    • Bleeke M, Fest S, Huebener N, et al. Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma. Eur J Cancer. 2009;45:2915-21.
    • (2009) Eur J Cancer , vol.45 , pp. 2915-2921
    • Bleeke, M.1    Fest, S.2    Huebener, N.3
  • 64
    • 20244378964 scopus 로고    scopus 로고
    • DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses
    • Bolesta E, Kowalczyk A, Wierzbicki A, et al. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res. 2005;65:3410-8.
    • (2005) Cancer Res , vol.65 , pp. 3410-3418
    • Bolesta, E.1    Kowalczyk, A.2    Wierzbicki, A.3
  • 65
    • 10744226998 scopus 로고    scopus 로고
    • Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21
    • Ragupathi G, Livingston PO, Hood C, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003;9:5214-20.
    • (2003) Clin Cancer Res , vol.9 , pp. 5214-5220
    • Ragupathi, G.1    Livingston, P.O.2    Hood, C.3
  • 66
    • 84895814045 scopus 로고    scopus 로고
    • Phase I trial of a bivalent gangliosides vaccine in combination with beta-glucan for high-risk neuroblastoma in second or later remission
    • Kushner BH, Cheung IY, Modak S, et al. Phase I trial of a bivalent gangliosides vaccine in combination with beta-glucan for high-risk neuroblastoma in second or later remission. Clin Cancer Res. 2014;20(5):1375-82.
    • (2014) Clin Cancer Res , vol.20 , Issue.5 , pp. 1375-1382
    • Kushner, B.H.1    Cheung, I.Y.2    Modak, S.3
  • 67
    • 33645679838 scopus 로고    scopus 로고
    • A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group
    • Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res. 2006;12:1750-9.
    • (2006) Clin Cancer Res , vol.12 , pp. 1750-1759
    • Osenga, K.L.1    Hank, J.A.2    Albertini, M.R.3
  • 68
    • 79951886003 scopus 로고    scopus 로고
    • Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) phase II study
    • Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010;28:4969-75.
    • (2010) J Clin Oncol , vol.28 , pp. 4969-4975
    • Shusterman, S.1    London, W.B.2    Gillies, S.D.3
  • 69
    • 0030453784 scopus 로고    scopus 로고
    • Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy
    • Becker JC, Varki N, Gillies SD, et al. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest. 1996;98:2801-4.
    • (1996) J Clin Invest , vol.98 , pp. 2801-2804
    • Becker, J.C.1    Varki, N.2    Gillies, S.D.3
  • 70
    • 84865410508 scopus 로고    scopus 로고
    • Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention
    • Yang RK, Kalogriopoulos NA, Rakhmilevich AL, et al. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol. 2012;189:2656-64.
    • (2012) J Immunol , vol.189 , pp. 2656-2664
    • Yang, R.K.1    Kalogriopoulos, N.A.2    Rakhmilevich, A.L.3
  • 71
    • 84870975998 scopus 로고    scopus 로고
    • Phase II trial of hu14.18-IL2 for patients with metastatic melanoma
    • Albertini MR, Hank JA, Gadbaw B, et al. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother. 2012;61(12):2261-2271.
    • (2012) Cancer Immunol Immunother , vol.61 , Issue.12 , pp. 2261-2271
    • Albertini, M.R.1    Hank, J.A.2    Gadbaw, B.3
  • 72
    • 84855804372 scopus 로고    scopus 로고
    • Interleukin-15 biology and its therapeutic implications in cancer
    • Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012;33:35-41.
    • (2012) Trends Pharmacol Sci , vol.33 , pp. 35-41
    • Steel, J.C.1    Waldmann, T.A.2    Morris, J.C.3
  • 73
    • 0036625059 scopus 로고    scopus 로고
    • Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis
    • Metelitsa LS, Gillies SD, Super M, et al. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood. 2002;99:4166-73.
    • (2002) Blood , vol.99 , pp. 4166-4173
    • Metelitsa, L.S.1    Gillies, S.D.2    Super, M.3
  • 74
    • 80052601578 scopus 로고    scopus 로고
    • Use of NK cell activity in cure by transplant
    • Leung W. Use of NK cell activity in cure by transplant. Br J Haematol. 2011;155:14-29.
    • (2011) Br J Haematol , vol.155 , pp. 14-29
    • Leung, W.1
  • 75
    • 78649968328 scopus 로고    scopus 로고
    • Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy
    • Delgado DC, Hank JA, Kolesar J, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010;70:9554-61.
    • (2010) Cancer Res , vol.70 , pp. 9554-9561
    • Delgado, D.C.1    Hank, J.A.2    Kolesar, J.3
  • 76
    • 0026511704 scopus 로고
    • Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity
    • Kushner BH, Cheung NK. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood. 1992;79:1484-90.
    • (1992) Blood , vol.79 , pp. 1484-1490
    • Kushner, B.H.1    Cheung, N.K.2
  • 77
    • 0344327143 scopus 로고    scopus 로고
    • Therapeutic intervention with complement and beta-glucan in cancer
    • Ross GD, Vetvicka V, Yan J, et al. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology. 1999;42:61-74.
    • (1999) Immunopharmacology , vol.42 , pp. 61-74
    • Ross, G.D.1    Vetvicka, V.2    Yan, J.3
  • 78
    • 0027398448 scopus 로고
    • A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen
    • Diamond MS, Springer TA. A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol. 1993;120:545-56.
    • (1993) J Cell Biol , vol.120 , pp. 545-556
    • Diamond, M.S.1    Springer, T.A.2
  • 79
    • 0035999738 scopus 로고    scopus 로고
    • Oral (1 -> 3),(1 -> 4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma
    • Cheung NK, Modak S. Oral (1 -> 3),(1 -> 4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002;8:1217-23.
    • (2002) Clin Cancer Res , vol.8 , pp. 1217-1223
    • Cheung, N.K.1    Modak, S.2
  • 80
    • 2942593696 scopus 로고    scopus 로고
    • Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma
    • Ren Y, Chan HM, Li Z, et al. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene. 2004;23:4146-54.
    • (2004) Oncogene , vol.23 , pp. 4146-4154
    • Ren, Y.1    Chan, H.M.2    Li, Z.3
  • 81
    • 77956976681 scopus 로고    scopus 로고
    • Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm
    • Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889-96.
    • (2010) Nat Immunol , vol.11 , pp. 889-896
    • Biswas, S.K.1    Mantovani, A.2
  • 82
    • 0024378215 scopus 로고
    • Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated anti-tumor cytotoxicity not detected by isotope release assays
    • Munn DH, Cheung NK. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated anti-tumor cytotoxicity not detected by isotope release assays. J Exp Med. 1989;170:511-26.
    • (1989) J Exp Med , vol.170 , pp. 511-526
    • Munn, D.H.1    Cheung, N.K.2
  • 83
    • 79952090734 scopus 로고    scopus 로고
    • Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion
    • Ladenstein R, Potschger U, Siabalis D, et al. Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion. J Clin Oncol. 2011;29:441-8.
    • (2011) J Clin Oncol , vol.29 , pp. 441-448
    • Ladenstein, R.1    Potschger, U.2    Siabalis, D.3
  • 84
    • 70350511426 scopus 로고    scopus 로고
    • Safety and immunologic effects of IL-15 administration in non-human primates
    • Berger C, Berger M, Hackman RC, et al. Safety and immunologic effects of IL-15 administration in non-human primates. Blood. 2009;114:2417-26.
    • (2009) Blood , vol.114 , pp. 2417-2426
    • Berger, C.1    Berger, M.2    Hackman, R.C.3
  • 85
    • 2442547655 scopus 로고    scopus 로고
    • Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2
    • Metelitsa LS, Wu HW, Wang H, et al. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med. 2004;199:1213-21.
    • (2004) J Exp Med , vol.199 , pp. 1213-1221
    • Metelitsa, L.S.1    Wu, H.W.2    Wang, H.3
  • 86
    • 84861801527 scopus 로고    scopus 로고
    • IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity
    • Liu D, Song L, Wei J, et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012;122:2221-33.
    • (2012) J Clin Invest , vol.122 , pp. 2221-2233
    • Liu, D.1    Song, L.2    Wei, J.3
  • 87
    • 33644975335 scopus 로고    scopus 로고
    • Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins
    • Mortier E, Quemener A, Vusio P, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem. 2006;281:1612-9.
    • (2006) J Biol Chem , vol.281 , pp. 1612-1619
    • Mortier, E.1    Quemener, A.2    Vusio, P.3
  • 88
    • 84877964989 scopus 로고    scopus 로고
    • Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its anti-tumor potency
    • Vincent M, Bessard A, Cochonneau D, et al. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its anti-tumor potency. Int J Cancer. 2013;133:757-65.
    • (2013) Int J Cancer , vol.133 , pp. 757-765
    • Vincent, M.1    Bessard, A.2    Cochonneau, D.3
  • 89
    • 84877809580 scopus 로고    scopus 로고
    • Current concepts in MRI of focal and diffuse malignancy of bone marrow
    • Howe BM, Johnson GB, Wenger DE. Current concepts in MRI of focal and diffuse malignancy of bone marrow. Semin Musculoskelet Radiol. 2013;17:137-44.
    • (2013) Semin Musculoskelet Radiol , vol.17 , pp. 137-144
    • Howe, B.M.1    Johnson, G.B.2    Wenger, D.E.3
  • 90
    • 33947688082 scopus 로고    scopus 로고
    • Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion
    • Qian J, Liu T, Yang L, et al. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem. 2007;364:8-18.
    • (2007) Anal Biochem , vol.364 , pp. 8-18
    • Qian, J.1    Liu, T.2    Yang, L.3
  • 91
    • 0027367160 scopus 로고
    • One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody
    • Galili U, Anaraki F, Thall A, et al. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood. 1993;82:2485-93.
    • (1993) Blood , vol.82 , pp. 2485-2493
    • Galili, U.1    Anaraki, F.2    Thall, A.3
  • 92
    • 0036872920 scopus 로고    scopus 로고
    • Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum
    • Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation. 2002;9:376-81.
    • (2002) Xenotransplantation , vol.9 , pp. 376-381
    • Zhu, A.1    Hurst, R.2
  • 93
    • 80051811754 scopus 로고    scopus 로고
    • Fatal infusion reaction to cetuximab: The need for predictive risk factors and safer patient selection
    • Tronconi MC, Sclafani F, Rimassa L, et al. Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection. J Clin Oncol. 2011;29:e680-1.
    • (2011) J Clin Oncol , vol.29 , pp. e680-e681
    • Tronconi, M.C.1    Sclafani, F.2    Rimassa, L.3
  • 94
    • 79960215653 scopus 로고    scopus 로고
    • Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains
    • Lammerts van Bueren JJ, Rispens T, Verploegen S, et al. Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 2011;29:574-6.
    • (2011) Nat Biotechnol , vol.29 , pp. 574-576
    • Lammerts Van Bueren, J.J.1    Rispens, T.2    Verploegen, S.3
  • 96
    • 80053082300 scopus 로고    scopus 로고
    • A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity
    • Alvarez-Rueda N, Desselle A, Cochonneau D, et al. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity. PLoS ONE. 2011;6:e25220.
    • (2011) PLoS ONE , vol.6 , pp. e25220
    • Alvarez-Rueda, N.1    Desselle, A.2    Cochonneau, D.3
  • 97
    • 84906085030 scopus 로고    scopus 로고
    • Antibody drug conjugates
    • Teicher BA. Antibody drug conjugates. Curr Opin Oncol. 2014;26:476-83.
    • (2014) Curr Opin Oncol , vol.26 , pp. 476-483
    • Teicher, B.A.1
  • 98
    • 84892369775 scopus 로고    scopus 로고
    • Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
    • Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014;588:288-97.
    • (2014) FEBS Lett , vol.588 , pp. 288-297
    • Ahmed, M.1    Cheung, N.K.2
  • 99
    • 64649084383 scopus 로고    scopus 로고
    • Radiation-induced bystander signalling in cancer therapy
    • Prise KM, O'Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer. 2009;9:351-60.
    • (2009) Nat Rev Cancer , vol.9 , pp. 351-360
    • Prise, K.M.1    O'Sullivan, J.M.2
  • 100
    • 0008942168 scopus 로고    scopus 로고
    • Monoclonal antibodies: Basic principles - Radioisotope conjugates
    • DeVita VT, Hellman S, Rosenberg SA, editors. Philadelphia: Lippincott
    • Larson SM, Divgi C, Sgouros G, et al. Monoclonal antibodies: basic principles - radioisotope conjugates. In: DeVita VT, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer - principles and practice. Philadelphia: Lippincott; 2000. p. 396-412.
    • (2000) Biologic Therapy of Cancer - Principles and Practice , pp. 396-412
    • Larson, S.M.1    Divgi, C.2    Sgouros, G.3
  • 101
    • 77957200514 scopus 로고    scopus 로고
    • Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma
    • Croog VJ, Kramer K, Cheung NK, et al. Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2010;78(3):849-54.
    • (2010) Int J Radiat Oncol Biol Phys , vol.78 , Issue.3 , pp. 849-854
    • Croog, V.J.1    Kramer, K.2    Cheung, N.K.3
  • 103
    • 36849018928 scopus 로고    scopus 로고
    • Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8
    • Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25:5465-70.
    • (2007) J Clin Oncol , vol.25 , pp. 5465-5470
    • Kramer, K.1    Humm, J.L.2    Souweidane, M.M.3
  • 104
    • 77953288400 scopus 로고    scopus 로고
    • Compartmental intrathecal radioimmunotherapy: Results for treatment for metastatic CNS neuroblastoma
    • Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol. 2010;97:409-18.
    • (2010) J Neurooncol , vol.97 , pp. 409-418
    • Kramer, K.1    Kushner, B.H.2    Modak, S.3
  • 105
    • 79551688075 scopus 로고    scopus 로고
    • Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging
    • Orcutt KD, Slusarczyk AL, Cieslewicz M, et al. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol. 2011;38:223-33.
    • (2011) Nucl Med Biol , vol.38 , pp. 223-233
    • Orcutt, K.D.1    Slusarczyk, A.L.2    Cieslewicz, M.3
  • 106
    • 84893690105 scopus 로고    scopus 로고
    • The potential and hurdles of targeted alpha therapy - Clinical trials and beyond
    • Elgqvist J, Frost S, Pouget JP, et al. The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol. 2014;3:324.
    • (2014) Front Oncol , vol.3 , pp. 324
    • Elgqvist, J.1    Frost, S.2    Pouget, J.P.3
  • 107
    • 6044248953 scopus 로고    scopus 로고
    • Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2
    • Miederer M, McDevitt MR, Borchardt P, et al. Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clin Cancer Res. 2004;10:6985-92.
    • (2004) Clin Cancer Res , vol.10 , pp. 6985-6992
    • Miederer, M.1    McDevitt, M.R.2    Borchardt, P.3
  • 108
    • 0025133413 scopus 로고
    • Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy
    • Rotmensch J, Roeske J, Chen G, et al. Estimates of dose to intraperitoneal micrometastases from alpha and beta emitters in radioimmunotherapy. Gynecol Oncol. 1990;38:478-85.
    • (1990) Gynecol Oncol , vol.38 , pp. 478-485
    • Rotmensch, J.1    Roeske, J.2    Chen, G.3
  • 109
    • 79551511102 scopus 로고    scopus 로고
    • Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid
    • He P, Kramer K, Smith-Jones P, et al. Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. Eur J Nucl Med Mol Imaging. 2011;38:334-42.
    • (2011) Eur J Nucl Med Mol Imaging , vol.38 , pp. 334-342
    • He, P.1    Kramer, K.2    Smith-Jones, P.3
  • 110
    • 68249160655 scopus 로고    scopus 로고
    • A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases
    • Lv Y, Cheung NK, Fu BM. A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases. J Nucl Med. 2009;50:1324-31.
    • (2009) J Nucl Med , vol.50 , pp. 1324-1331
    • Lv, Y.1    Cheung, N.K.2    Fu, B.M.3
  • 111
    • 33644869654 scopus 로고    scopus 로고
    • Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy
    • Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006;24:823-34.
    • (2006) J Clin Oncol , vol.24 , pp. 823-834
    • Goldenberg, D.M.1    Sharkey, R.M.2    Paganelli, G.3
  • 112
    • 84904174507 scopus 로고    scopus 로고
    • Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex
    • Cheal SM, Xu H, Guo HF, et al. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther. 2014;13:1803-12.
    • (2014) Mol Cancer Ther , vol.13 , pp. 1803-1812
    • Cheal, S.M.1    Xu, H.2    Guo, H.F.3
  • 113
    • 2642527143 scopus 로고    scopus 로고
    • Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2
    • Cheung NK, Modak S, Lin Y, et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J Nucl Med. 2004;45:867-77.
    • (2004) J Nucl Med , vol.45 , pp. 867-877
    • Cheung, N.K.1    Modak, S.2    Lin, Y.3
  • 114
    • 0037401058 scopus 로고    scopus 로고
    • In vitro and in vivo anti-tumor activity of liposomal Fenretinide targeted to human neuroblastoma
    • Raffaghello L, Pagnan G, Pastorino F, et al. In vitro and in vivo anti-tumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int J Cancer. 2003;104:559-67.
    • (2003) Int J Cancer , vol.104 , pp. 559-567
    • Raffaghello, L.1    Pagnan, G.2    Pastorino, F.3
  • 115
    • 0037224431 scopus 로고    scopus 로고
    • Doxorubicin-loaded Fab' fragments of antidisialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice
    • Pastorino F, Brignole C, Marimpietri D, et al. Doxorubicin-loaded Fab' fragments of antidisialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 2003;63:86-92.
    • (2003) Cancer Res , vol.63 , pp. 86-92
    • Pastorino, F.1    Brignole, C.2    Marimpietri, D.3
  • 116
    • 3543119461 scopus 로고    scopus 로고
    • Immune cell-mediated anti-tumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs
    • Brignole C, Pastorino F, Marimpietri D, et al. Immune cell-mediated anti-tumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J Natl Cancer Inst. 2004;96:1171-80.
    • (2004) J Natl Cancer Inst , vol.96 , pp. 1171-1180
    • Brignole, C.1    Pastorino, F.2    Marimpietri, D.3
  • 117
    • 84861473531 scopus 로고    scopus 로고
    • Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles
    • Tivnan A, Orr WS, Gubala V, et al. Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE. 2012;7:e38129.
    • (2012) PLoS ONE , vol.7 , pp. e38129
    • Tivnan, A.1    Orr, W.S.2    Gubala, V.3
  • 118
    • 34249812122 scopus 로고    scopus 로고
    • MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells
    • Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007;26:5017-22.
    • (2007) Oncogene , vol.26 , pp. 5017-5022
    • Welch, C.1    Chen, Y.2    Stallings, R.L.3
  • 119
    • 42049092138 scopus 로고    scopus 로고
    • Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest
    • Sun F, Fu H, Liu Q, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008;582:1564-8.
    • (2008) FEBS Lett , vol.582 , pp. 1564-1568
    • Sun, F.1    Fu, H.2    Liu, Q.3
  • 120
    • 77953920780 scopus 로고    scopus 로고
    • MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells
    • Pang RT, Leung CO, Ye TM, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis. 2010;31:1037-44.
    • (2010) Carcinogenesis , vol.31 , pp. 1037-1044
    • Pang, R.T.1    Leung, C.O.2    Ye, T.M.3
  • 121
    • 84885124167 scopus 로고    scopus 로고
    • Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma
    • Di Paolo D, Pastorino F, Zuccari G, et al. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma. J Control Release. 2013;170:445-51.
    • (2013) J Control Release , vol.170 , pp. 445-451
    • Di Paolo, D.1    Pastorino, F.2    Zuccari, G.3
  • 122
    • 79953697128 scopus 로고    scopus 로고
    • Anti-neuroblastoma activity of gold nanorods bound with GD2 monoclonal antibody under near-infrared laser irradiation
    • Peng CA, Wang CH. Anti-neuroblastoma activity of gold nanorods bound with GD2 monoclonal antibody under near-infrared laser irradiation. Cancers (Basel). 2011;3:227-40.
    • (2011) Cancers (Basel) , vol.3 , pp. 227-240
    • Peng, C.A.1    Wang, C.H.2
  • 123
    • 67849086444 scopus 로고    scopus 로고
    • In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody
    • Wang CH, Huang YJ, Chang CW, et al. In vitro photothermal destruction of neuroblastoma cells using carbon nanotubes conjugated with GD2 monoclonal antibody. Nanotechnology. 2009;20:315101.
    • (2009) Nanotechnology , vol.20 , pp. 315101
    • Wang, C.H.1    Huang, Y.J.2    Chang, C.W.3
  • 124
    • 33845294816 scopus 로고    scopus 로고
    • CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and anti-tumor efficacy of adoptively transferred T cells
    • Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and anti-tumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66:10995-1004.
    • (2006) Cancer Res , vol.66 , pp. 10995-11004
    • Kowolik, C.M.1    Topp, M.S.2    Gonzalez, S.3
  • 125
    • 62549097817 scopus 로고    scopus 로고
    • Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
    • Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009;106:3360-5.
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 3360-3365
    • Carpenito, C.1    Milone, M.C.2    Hassan, R.3
  • 126
    • 55549145071 scopus 로고    scopus 로고
    • Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and anti-tumor activity in individuals with neuroblastoma
    • Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and anti-tumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-70.
    • (2008) Nat Med , vol.14 , pp. 1264-1270
    • Pule, M.A.1    Savoldo, B.2    Myers, G.D.3
  • 127
    • 82955207691 scopus 로고    scopus 로고
    • Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
    • Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118:6050-6.
    • (2011) Blood , vol.118 , pp. 6050-6056
    • Louis, C.U.1    Savoldo, B.2    Dotti, G.3
  • 128
    • 84883192533 scopus 로고    scopus 로고
    • Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging
    • Liebsch L, Kailayangiri S, Beck L, et al. Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging. Br J Cancer. 2013;109:658-66.
    • (2013) Br J Cancer , vol.109 , pp. 658-666
    • Liebsch, L.1    Kailayangiri, S.2    Beck, L.3
  • 129
    • 84856267795 scopus 로고    scopus 로고
    • NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
    • Esser R, Muller T, Stefes D, et al. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med. 2012;16:569-81.
    • (2012) J Cell Mol Med , vol.16 , pp. 569-581
    • Esser, R.1    Muller, T.2    Stefes, D.3
  • 130
    • 17644385543 scopus 로고    scopus 로고
    • Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
    • Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer. 2005;115:98-104.
    • (2005) Int J Cancer , vol.115 , pp. 98-104
    • Hoffmann, P.1    Hofmeister, R.2    Brischwein, K.3
  • 131
    • 49649120397 scopus 로고    scopus 로고
    • Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
    • Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974-7.
    • (2008) Science , vol.321 , pp. 974-977
    • Bargou, R.1    Leo, E.2    Zugmaier, G.3
  • 132
    • 84921332022 scopus 로고    scopus 로고
    • Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy
    • PMID:24895182
    • Cheng M, Ahmed M, Xu H, et al. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer. 2014 PMID:24895182.
    • (2014) Int J Cancer
    • Cheng, M.1    Ahmed, M.2    Xu, H.3
  • 134
    • 84867375009 scopus 로고    scopus 로고
    • Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets
    • Yankelevich M, Kondadasula SV, Thakur A, et al. Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer. 2012;59(7):1198-205.
    • (2012) Pediatr Blood Cancer , vol.59 , Issue.7 , pp. 1198-1205
    • Yankelevich, M.1    Kondadasula, S.V.2    Thakur, A.3
  • 135
    • 84865115651 scopus 로고    scopus 로고
    • Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect
    • Eissler N, Ruf P, Mysliwietz J, et al. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res. 2012;72:3958-66.
    • (2012) Cancer Res , vol.72 , pp. 3958-3966
    • Eissler, N.1    Ruf, P.2    Mysliwietz, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.